Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 9/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 8/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 5/20 | 1.00 |
| ▸ | APP | P05067 | 5/20 | 1.00 |
| ▸ | NR4A2 | P43354 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | CYP2J2 | P51589 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 1.00 |
| ▸ | CYP2C8 | P10632 | 6/20 | 0.98 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amodiaquine SCHEMBL29441086 | 1.00 | CYP2D6 (1.00) | CYP2D6CYP1A2KCNH2APPNR4A2 | |
| Amodiaquine SCHEMBL44152 | 1.00 | CYP2D6 (1.00) | CYP2D6CYP1A2KCNH2APPNR4A2 | |
| Amodiaquine SCHEMBL317888 | 0.99 | CYP2D6 (1.00) | CYP2D6CYP1A2KCNH2APPNR4A2 | |
| Amodiaquine SCHEMBL12094969 | 0.99 | CYP2D6 (1.00) | CYP2D6CYP1A2KCNH2APPNR4A2 | |
| Amodiaquine SCHEMBL29430175 | 0.99 | CYP2D6 (1.00) | CYP2D6CYP1A2KCNH2APPNR4A2 | |
| Amodiaquine SCHEMBL29788983 | 0.99 | CYP2D6 (1.00) | CYP2D6CYP1A2KCNH2APPNR4A2 | |
| Amodiaquine SCHEMBL1491204 | 0.98 | CYP2D6 (1.00) | CYP2D6CYP1A2KCNH2APPNR4A2 | |
| Amodiaquine SCHEMBL284774 | 0.98 | CYP2D6 (0.96) | CYP2D6CYP1A2KCNH2APPNR4A2 | |
| Amodiaquine SCHEMBL30903900 | 0.98 | CYP2D6 (1.00) | CYP2D6CYP1A2KCNH2APPNR4A2 | |
| SCHEMBL20536537 | 0.94 | CYP2D6 (0.88) | CYP2D6CYP1A2KCNH2APPNR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250269005-A1 | METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT | TOPELIA AUST LIMITED (ACN 652 771 670) (AU) | 2025-08-28 | — | — | US | claimed |
| EP-4337179-A1 | METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT | Topelia Aust Limited (ACN 652 771 670) (AU) | 2024-03-20 | — | — | EP | claimed |
| WO-2022236364-A1 | METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT | TOPELIA AUST LIMITED (ACN 652 771 670) (AU) | 2022-11-17 | — | — | WO | claimed |
| WO-2022214855-A1 | USE OF NITAZOXANIDE TO PREPARE A MEDICINAL PRODUCT TO PREVENT OR TREAT CORONAVIRUS SARS-COV-2 INFECTION | SIEGFRIED RHEIN, S.A. DE C.V. (MX) | 2022-10-13 | — | — | WO | claimed |
| CN-114118146-A | Rolling bearing fault diagnosis method and system based on belief rule base | 南京晨光集团有限责任公司 | 2022-03-01 | — | — | CN | claimed |
| CN-121574131-A | Heterocyclic compounds for insect repellent | 勃林格殷格翰动物保健有限公司 | 2026-02-27 | — | — | CN | disclosed |
| US-20250269005-A1 | METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT | TOPELIA AUST LIMITED (ACN 652 771 670) (AU) | 2025-08-28 | — | — | US | disclosed |
| WO-2025133005-A1 | IONISING RADIATION DETECTOR | ELECTRICITE DE FRANCE (FR) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025052381-A1 | INHIBITORS AND COMBINATIONS FOR TREATING DISEASES | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2025-03-13 | — | — | WO | disclosed |
| US-12233122-B2 | Methods for treating, ameliorating or preventing infections using drug and vaccination combination treatment | TOPELIA AUST LIMITED (652 771 670) (AU) | 2025-02-25 | — | — | US | disclosed |
| US-20240382578-A1 | METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT | TOPELIA AUST LTD 652 771 670 (AU) | 2024-11-21 | — | — | US | disclosed |
| EP-4337179-A1 | METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT | Topelia Aust Limited (ACN 652 771 670) (AU) | 2024-03-20 | — | — | EP | disclosed |
| US-11857617-B2 | Methods for treating, ameliorating or preventing infections using drug and vaccination combination treatment | TOPELIA AUST LIMITED (652 771 670) (AU) | 2024-01-02 | — | — | US | disclosed |
| CN-115947684-A | Method for preparing 4-aminoquinoline derivatives through palladium and copper concerted catalytic oxidation aromatization | 贵州医科大学 | 2023-04-11 | — | — | CN | disclosed |
| CN-115943307-A | MR1 ligands and pharmaceutical compositions for immunomodulation | 巴塞尔大学 | 2023-04-07 | — | — | CN | disclosed |
| US-20220370589-A1 | METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT | TOPELIA AUST LIMITED (ACN 652 771 670) (AU) | 2022-11-24 | — | — | US | disclosed |
| WO-2022236364-A1 | METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT | TOPELIA AUST LIMITED (ACN 652 771 670) (AU) | 2022-11-17 | — | — | WO | disclosed |
| WO-2022214855-A1 | USE OF NITAZOXANIDE TO PREPARE A MEDICINAL PRODUCT TO PREVENT OR TREAT CORONAVIRUS SARS-COV-2 INFECTION | SIEGFRIED RHEIN, S.A. DE C.V. (MX) | 2022-10-13 | — | — | WO | disclosed |
| CN-114600329-A | Method and apparatus for controlled switching of coupled loads | 日立能源瑞士股份公司 | 2022-06-07 | — | — | CN | disclosed |
| CN-114118146-A | Rolling bearing fault diagnosis method and system based on belief rule base | 南京晨光集团有限责任公司 | 2022-03-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240382578-A1 | METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT | ACE, ACE2, CASP3 | CYP2D6 390/4885CYP1A2 1177/4885KCNH2 1886/4885 |
| US-12233122-B2 | Methods for treating, ameliorating or preventing infections using drug and vaccination combination treatment | ACE, ACE2, CASP3 | CYP2D6 390/4885CYP1A2 1177/4885KCNH2 1886/4885 |
| US-11857617-B2 | Methods for treating, ameliorating or preventing infections using drug and vaccination combination treatment | ZFX, IKZF3, ACE2 | CYP2D6 1348/4885CYP1A2 1203/4885KCNH2 533/4885 |
| US-20250269005-A1 | METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT | ZFX, ACE2, ZFR | CYP2D6 1552/4885CYP1A2 1173/4885KCNH2 613/4885 |
| US-20220370589-A1 | METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT | ZFX, IKZF3, ACE2 | CYP2D6 1348/4885CYP1A2 1203/4885KCNH2 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.